## (19) World Intellectual Property Organization International Bureau



A61K 38/13.



## (43) International Publication Date 15 March 2001 (15.03,2001) PCT

## (10) International Publication Number WO 01/17546 A1

9/50, 9/51	

(21) International Application Number: PCT/US00/24505 (22) International Filing Date:

7 September 2000 (07.09.2000)

(25) Filing Language: English (26) Publication Language: English

(30) Priority Data:

09/392,557 9 September 1999 (09.09,1999) US

(51) International Patent Classification?:

(63) Related by continuation (CON) or continuation-in-part

(CIP) to earlier application: US 09/392,557 (CIP) Filed on 9 September 1999 (09,09,1999)

(71) Applicant (for all designated States except US): ELAN PHARMA INTERNATIONAL LTD, [IE/IE]; Wil House, Shannon County Clare (IE).

(72) Inventors; and (75) Inventors/Applicants (for US only): BOSCH, H.,

William [US/US]; 237 Rodney Circle, Bryn Mawr. PA 19010 (US). OSTRANDER, Kevin, D. [US/US]; 227 Sunrise Road, Reading, PA 19606 (US), HOVEY, Douglas, C. [US/US]; 16 Hunt Club Drive, Collegeville, PA

(74) Agent: BENT, Stephen, A.; Foley & Lardner, 3000 K Street, NW, Suite 500, Washington, DC 20007-5109 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FJ, GB, GD, GE, GH, GM, HR. HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR. LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR. TT. TZ. UA. UG. US. UZ. VN. YU. ZA. ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


## Published:

19426 (US).

With international search report.

[Continued on next page]

(54) Title: NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS



(57) Abstract: Nanoparticulate amorphous cyclosporine formulations, and nanoparticulate cyclosporine formulations comprising a mixture of amorphous and crystalline cyclosporine, having effective average particle sizes of less than about 2000 nm are described. The compositions exhibit increased bioavailability and increased consistency of bioavailability as compared to prior macro-sized cyclosporine and formulations. Methods of making and using the compositions are also described.